<DOC>
	<DOCNO>NCT00209716</DOCNO>
	<brief_summary>A phase I/II study conduct determine maximum-tolerated dose ( MTD ) , dose-limiting toxicity ( DLT ) , efficacy combination chemotherapy use docetaxel , cisplatin 5-fluorouracil ( TPF ) Pre-treated patient metastatic esophageal cancer . The usefulness regimen evaluate response rate , median survival time , progression free survival .</brief_summary>
	<brief_title>Phase I/II Study Taxotere , CDDP 5-FU ( TPF ) Pre-treated Pts With Metastatic Esophageal Cancer .</brief_title>
	<detailed_description>Patients pre-treated measurable metastatic esophageal cancer include trial . Patients receive combination chemotherapy repeat every 28 day progression disease . Starting dose ( dose level 1 ) docetaxel 30 mg/m2 day 1 , fix dose intravenously cisplatin ( 15 mg/m2/day ) continuous infusion 5-FU ( 800 mg/m2/day ) day 1-4 . DLT define follow ( accord NCI-CTC version 2.0 ) ; Grade 4 neutropenia last 4days , Grade 4 anemia thrombocytopenia , Grade 3 neutropenia accompany fever ( &gt; 38℃ ) , Grade 3 non-hematological toxicity ( except nausea , appetite loss , general fatigue ) . Maximal Tolerated Dose ( MTD ) determine incidence critical toxicity exceed 50 % certain dose level . Response rate calculate accord RECIST criterion .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm metastatic recurrent esophageal tumor previous treatment advance disease . ( Except small cell carcinoma ) At least one measurable lesion accord RECIST criterion . Minimum indicator lesion size : &gt; 10 mm measure spiral CT &gt; 20mm measure conventional technique ( Except Phase I set ) . Patients age 20 75 year , inclusive , time acquisition inform consent Patients performance status ( ECOG ) 0 2 Abnormal hematologic value ( WBC ≥ 3.5 x 109/L , Hemoglobin ≥ 9.5g/dl , platelet count ≥ 100 x 109/L ) Creatinine clearance ≥ 60 ml/min , Serum cleatinine ≤ 1.5mg/dl Serum bilirubin ≤ 1.5mg/dl . ALT , AST ≤ 2.5 x upper normal limit ( ≤ 3 x upper normal limit case liver metastasis ) Patients receive 1cycle cancer therapy ( radiotherapy , chemotherapy chemoradiotherapy ) give &gt; 4 week prior begin study therapy Life expectancy ≥ 3 month Patients give write informed consent participate study Patients active multiple cancer ; even multiple cancer metachronous , diseasefree period le 5 year ( exclude cancer situ skin cancer ) ( Except Phase I set ) Serious , uncontrolled , concurrent infection ( ) illness ( es ) Patients serious concurrent complication ( heart disease , Intestinal pneumonia ) Patients brain metastasis Patients receive continuous administration steroid Patients experience serious drug allergy past Patients retention body fluid ( pleural effusion , ascites , pericardial effusion ) necessitate treatment Patients pregnant lactate hope become pregnant study period Patients prior Taxan treatment ( Paclitaxel , Docetaxel ) Patients edema ≥ grade 2 Others , patient judge investigator subinvestigator inappropriate subject</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>